Global biotech firm Amgen will open a new Science and Innovation Center in Hyderabad’s Genome Valley by 2027. This follows its 2025 technology hub launch in the city. Investors are monitoring the company’s ability to balance its $57.3 billion debt with ongoing investments in drug discovery and global research capabilities.
Amgen is expanding its global research footprint with a new Science and Innovation Center in Hyderabad’s Genome Valley, which is expected to be operational by 2027. This facility will work alongside the company’s existing global research network to combine experimental science with digital data and advanced technology. The goal is to speed up research initiatives that support the company's drug development pipeline.
This is the second major expansion for Amgen in Hyderabad. In February 2025, the company opened a technology and innovation hub in HITEC City, supported by a $200 million investment commitment. The move into Genome Valley signals that Amgen is shifting its focus in India from purely technology support to core, high-end scientific research. For the region, this adds to the growing cluster of life sciences organizations leveraging local scientific talent.
Amgen recently reported strong financial results for the second quarter of 2026, with revenue crossing $10 billion, representing a 10% increase compared to the previous year. While the company holds a solid cash position of $14 billion as of June 30, 2026, it also manages a total debt load of $57.3 billion. This debt level is an important point for investors, as the biotechnology sector often requires heavy, continuous spending on research to remain competitive.
Investors tracking the biotech industry often watch for the risks inherent in drug discovery, including the long timelines for clinical trials and the high probability of regulatory hurdles. Success in these new research centers is never guaranteed, as it depends on finding successful new drug candidates and securing patent protections. Furthermore, the company faces ongoing competitive pressure in high-value segments, such as cardiovascular health and obesity treatments, where new therapies and lower-cost biosimilars continue to enter the market.
The next major milestone for stakeholders is the construction progress leading up to the 2027 launch. Beyond this project, investors are expected to track the company’s ability to maintain its profit margins while balancing the heavy cost of global research and the repayment of its significant debt obligations.